EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genetic variability of CYP2D6, CYP2C19, and CYP1A2 in patients with treatment resistance to antipsychotics and antidepressants

Tatiana A Zhiganova iD, Evgenia A Radkova iD

Folia Medica · 2025

DOI: 10.3897/folmed.67.e149527 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Folia Medica, 2025. Verfasst von Tatiana A Zhiganova und 1 weiteren Autor:innen. Beteiligte Einrichtung: Dynasty Medical Centers, Saint Petersburg, Russia. Hauptthemen laut MEDLINE: Antipsychotic Agents, Antidepressive Agents, Cytochrome P-450 CYP2C19, Cytochrome P-450 CYP2D6. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The study objective was to assess the frequency of gene alleles responsible for the metabolism and elimination of drugs in treatment-resistant patients to antipsychotics and/or antidepressants. Materials and methods : The frequency of CYP2D6, CYP2C19, and CYP1A2 gene alleles was studied in 133 patients aged 18–70 years in comparison with a healthy population.  Results : Patients with treatment resistance to antipsychotics and/or antidepressants demonstrated the increased allele frequency of CYP2D6 *3 (4.5% vs. 1.0%, OR 4.5, p =0.003), CYP2C19 *17 (24.4% vs. 15.4%, OR 1.78, p =0.027), CYP1A2 *1A (68.5% vs. 41.4%, OR 3.03, p <0.001), decreased allele frequency of CYP2C19 *1 (61.3% vs. 88.3%, OR 0.21, p <0.001) and CYP1A2 *1F (30.4% vs. 58.6%, p <0.001). The frequency of CYP2D6 *5 allele was higher in females (3.8% vs. 0% in males, OR 11.6, p =0.029). No age difference was found in CYP2D6, CYP2C19, and CYP1A2 alleles frequencies in the subgroups of patients aged 18–30 years versus 31–70 years.

Conclusion

The observed difference in the genotype prevalence of CYP2D6, CYP2C19, and CYP1A2 in patients with antipsychotic and/or antidepressant resistance allows us to recommend pharmacogenetic testing for routine clinical practice in order to select the most effective and safe treatment for patients with antipsychotic and antidepressant resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsAntidepressive AgentsCytochrome P-450 CYP2C19Cytochrome P-450 CYP2D6Cytochrome P-450 CYP1A2HumansFemaleMaleMiddle AgedAdultAllelesGenetic VariationDrug ResistanceGenotype

Stichwörter der Autor:innen

allele polymorphism cytochrome pharmacogenetic testing

Substanzen

Antipsychotic AgentsAntidepressive AgentsCytochrome P-450 CYP2C19Cytochrome P-450 CYP2D6Cytochrome P-450 CYP1A2CYP2C19 protein, humanCYP1A2 protein, human

Autor:innen und Institutionen

  • Dynasty Medical Centers, Saint Petersburg, Russia.
  • OST-RUS, Saint Petersburg, Russia.

ORCID-Profile: Tatiana A Zhiganova, Evgenia A Radkova

Zitieren

APA

Zhiganova, T. A., & Radkova, E. A. (2025). Genetic variability of CYP2D6, CYP2C19, and CYP1A2 in patients with treatment resistance to antipsychotics and antidepressants. Folia Medica. https://doi.org/10.3897/folmed.67.e149527

Vancouver

Zhiganova TA, Radkova EA. Genetic variability of CYP2D6, CYP2C19, and CYP1A2 in patients with treatment resistance to antipsychotics and antidepressants. Folia Medica. 2025. doi:10.3897/folmed.67.e149527

BibTeX
@article{Zhiganova2025,
  author = {Zhiganova, Tatiana A and Radkova, Evgenia A},
  title = {Genetic variability of CYP2D6, CYP2C19, and CYP1A2 in patients with treatment resistance to antipsychotics and antidepressants},
  journal = {Folia Medica},
  year = {2025},
  doi = {10.3897/folmed.67.e149527}
}
Kostenlos starten →